Skip to main content
. 2018 May 24;73(9):2529–2539. doi: 10.1093/jac/dky184

Figure 4.

Figure 4.

Probabilistic sensitivity analysis: cost-effectiveness acceptability curve. EPFX, extended-pulsed fidaxomicin.